Trial Profile

A Prospective, Open-label, Platform Study for Long-term Follow-up of Participants Using Study Intervention in Pulmonary Hypertension Parent Studies

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 25 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Macitentan (Primary) ; Macitentan/tadalafil (Primary) ; Selexipag (Primary)
Indications Pulmonary hypertension
Focus Adverse reactions
Acronyms PLATYPUS
Sponsors Actelion Pharmaceuticals

Most Recent Events

24 Mar 2025 Planned number of patients changed from 390 to 280.
24 Mar 2025 Planned End Date changed from 29 Feb 2028 to 28 Sep 2029.
04 Dec 2024 Planned End Date changed from 24 May 2027 to 29 Feb 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com